Boston Scientific Corporation $BSX Shares Acquired by Security National Bank

Security National Bank raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 52.3% during the second quarter, HoldingsChannel reports. The firm owned 74,682 shares of the medical equipment provider’s stock after buying an additional 25,654 shares during the period. Security National Bank’s holdings in Boston Scientific were worth $3,187,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of BSX. Brighton Jones LLC lifted its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth about $26,000. Main Street Financial Solutions LLC raised its stake in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares during the last quarter. Ieq Capital LLC raised its stake in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its holdings in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.4%

BSX stock opened at $51.40 on Thursday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a 50 day simple moving average of $45.94 and a 200-day simple moving average of $59.69. The company has a market capitalization of $74.49 billion, a P/E ratio of 20.81, a PEG ratio of 1.12 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the business posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Truist Financial decreased their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Robert W. Baird set a $56.00 price target on Boston Scientific in a research note on Thursday, July 30th. Finally, UBS Group lowered their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Buying and Selling

In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have purchased 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.